Results 71 to 80 of about 435,241 (348)

MODERN STATUS OF VACCINE PROPHYLAXIS OF MUMPS

open access: yesИнфекция и иммунитет, 2014
. Vaccination against mumps is conducted in Russian Federation since 1981. This made it possible to decrease mumps incidence more than 600 times in compare with pre-vaccination period.
E. O. Kontarova   +3 more
doaj   +1 more source

Was EU’s COVID-19 vaccine procurement strategy irrational? A re-analysis based on cost-effectiveness considerations

open access: yesBMC Health Services Research, 2022
Aim The European Union (EU) has received criticism for being slow to secure coronavirus disease (COVID-19) vaccine contracts in 2020 before the approval of the first COVID-19 vaccine.
Afschin Gandjour
doaj   +1 more source

Shoring Up Vaccine Efficacy [PDF]

open access: yesThe American Journal of Medicine, 2022
Saray Stancic   +2 more
openaire   +2 more sources

Nano‐ and Micro‐Sized Solid Materials Used as Antiviral Agents

open access: yesAdvanced Functional Materials, EarlyView.
Due to the rise of viral infections in humans and possible viral outbreaks, the use of nano‐ or micro‐sized materials as antiviral agents is rapidly increasing. This review explores their antiviral properties against RNA and DNA viruses, either as a prevention or a treatment tool, by delving into their mechanisms of action and how to properly assess ...
Orfeas‐Evangelos Plastiras   +6 more
wiley   +1 more source

Estimating vaccine efficacy during open-label follow-up of COVID-19 vaccine trials based on population-level surveillance data

open access: yesEpidemics
While rapid development and roll out of COVID-19 vaccines is necessary in a pandemic, the process limits the ability of clinical trials to assess longer-term vaccine efficacy. We leveraged COVID-19 surveillance data in the U.S.
Mia Moore   +10 more
doaj   +1 more source

Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges. [PDF]

open access: yes, 2019
Introduction: Tuberculosis (TB) remains a major health threat and it is now clear that the current vaccine, BCG, is unable to arrest the global TB epidemic. A new vaccine is needed to either replace or boost BCG so that a better level of protection could
Barclay WR   +8 more
core   +1 more source

Poly(lactic‐co‐glycolic acid) Nanoparticles for IL‐12 Self‐Amplifying RNA Delivery in Glioblastoma Models

open access: yesAdvanced Functional Materials, EarlyView.
xxxx. ABSTRACT Glioblastoma (GBM) remains one of the most lethal brain cancers, with median survival rarely exceeding 15 months after diagnosis. Interleukin‐12 (IL‐12) is a potent immunostimulatory cytokine capable of reshaping the tumor microenvironment (TME), yet its clinical translation is hindered by systemic toxicity and short half‐life. RNA‐based
Fatima Hameedat   +11 more
wiley   +1 more source

Intention-to-prevent analyses for estimating human papillomavirus vaccine efficacy in clinical studies

open access: yesContemporary Clinical Trials Communications, 2017
HPV vaccine efficacy trials have been conducted in populations exposed to HPV infection (i.e., sexually active individuals); participants were not excluded from participating in the trials based on their HPV status at baseline.
Alfred Saah   +3 more
doaj   +1 more source

Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine. [PDF]

open access: yes, 2011
BACKGROUND\ud \ud A pivotal phase III study of the RTS,S/AS01 malaria candidate vaccine is ongoing in several research centres across Africa. The development and establishment of quality systems was a requirement for trial conduct to meet international ...
Adriano Duse   +17 more
core   +3 more sources

Home - About - Disclaimer - Privacy